Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Research & Development (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Research & Development for 6 consecutive years, with $152.9 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development rose 26.9% year-over-year to $152.9 million, compared with a TTM value of $821.7 million through Jun 2025, up 75.41%, and an annual FY2025 reading of $550.4 million, up 25.12% over the prior year.
  • Research & Development was $152.9 million for Q2 2025 at Roivant Sciences, down from $405.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $405.2 million in Q4 2024 and bottomed at $78.5 million in Q2 2021.
  • Average Research & Development over 5 years is $156.4 million, with a median of $132.0 million recorded in 2022.
  • The sharpest move saw Research & Development tumbled 48.09% in 2022, then skyrocketed 227.5% in 2024.
  • Year by year, Research & Development stood at $137.3 million in 2021, then dropped by 8.6% to $125.5 million in 2022, then fell by 1.45% to $123.7 million in 2023, then surged by 227.5% to $405.2 million in 2024, then plummeted by 62.26% to $152.9 million in 2025.
  • Business Quant data shows Research & Development for ROIV at $152.9 million in Q2 2025, $405.2 million in Q4 2024, and $143.1 million in Q3 2024.